Clinical Trial Update: Lenalidomide Plus Rituximab (R) in Non Follicular NHL [Phase 2]

View source ↗

Summary

Phase 2 trial update of lenalidomide plus rituximab in indolent non-Hodgkin lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Gruppo Italiano Studio Linfomi | Conditions: Indolent Non Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN